



GP 163

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Applicati n	09/391,606	
	Filing Date	September 7, 1999	
	First Named	Andrew D. Murdin	
	Group Art Unit	1633	
	Examiner Name	M. Wilson	
Total Number of Pages in This Submission	4	Attorney Docket Number	1038-971 MIS

TECH CENTER 1600/2900
MAY - 1 2001
RECEIVED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Restriction requirement response
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Michael I. Stewart - Reg. No. 24,973
Signature	<i>M. I. Stewart</i>
Date	April 26, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>			
Typed or printed name			
Signature		Date	

⊕ Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#12/10
5/1/01
RECEIVED
MAY - 1 2001
TECH CENTER 1600/2900

Applicant : Andrew D. Murdin. et al
Appl'n. No. : 09/391,606
Filed : September 7, 1999
Title : IMMUNOGENIC COMPOSITIONS FOR PROTECTION
AGAINST CHLAMYDIAL INFECTION
Grp./A.U. : 1633
Examiner : M. Wilson
Docket No. : 1038-971 MIS

April 26, 2001

BY COURIER

The Commissioner of Patents
and Trademarks,
Washington, D.C. 20231,
U.S.A.

Sir:

This Communication is in response to the Office Action of March 28, 2001.

The Examiner required election of one SEQ ID NO: as the first nucleic acid and one SEQ NO: as the second nucleic acid. In view of the requirement, the applicants elect SEQ ID NO: 13 as the first nucleic acid and SEQ ID NO: 3 as the second nucleic acid.

The Examiner's justification for the restriction requirement as contained in the Office Action is that:

"... the numerous sequences encompassed by the claims require too much time to search and the search is considered burdensome."

Applicants have already been subject to one restriction requirement with respect to the species of *Chlamydia*. Applicants claim 1 is not limited to any specific SEQ ID NO.



MAY - 1 2001

TECH CENTER 1600/2900

With respect to the SEQ ID NOs. specified in subsidiary claims, it is submitted that there is no undue burden. The SEQ ID's are identified as follows:

Figure 1 shows the nucleotide sequence of *C. pneumoniae* 76 kDa gene:

- SEQ ID NO:1 – complete sequence
- SEQ ID NO:2 – 5' encoding region
- SEQ ID NO:3 – 3' encoding region including Myc and His encoding regions
- SEQ ID NO:4 – 3' encoding region excluding Myc and His encoding regions
- SEQ ID NO:5 – Myc encoding region
- SEQ ID NO:7 – amino acid sequence encoded by upstream reading frame
- SEQ ID NO:8 – amino acid sequence encoded by downstream reading frame including Myc and His regions
- SEQ ID NO:9 – amino acid sequence encoded by downstream reading frame excluding Myc and His regions
- SEQ ID NO:10 – amino acid sequence of Myc region
- SEQ ID NO:11 – amino acid sequence of His region

Accordingly, SEQ ID NOS: 1 to 11 all relate to the same nucleotide sequence and hence there is no undue burden presented by the individual sequences identified by SEQ ID NOS: 1 to 11.

Figure 3 shows the nucleotide sequence of *C. pneumoniae* MOMP gene:

- SEQ ID NO:12 – complete sequence
- SEQ ID NO:13 – encoding sequence including Myc and His encoding regions
- SEQ ID NO:14 – encoding sequence excluding Myc and His encoding regions
- SEQ ID NO:15 – amino acid sequence of the MOMP protein, including Myc and His regions
- SEQ ID NO:16 – amino acid sequence of the MOMP protein excluding Myc and His regions

Accordingly, SEQ ID NOS: 12 to 16 all relate to the same nucleotide sequence and hence there is no undue burden presented by individual sequences identified by SEQ ID NOS: 12 to 16.



RECEIVED

MAY - 1 2001

TECH CENTER 1600/2900

The various SEQ ID NOS., therefore, relate to two gene sequences, namely that of the *C. pneumoniae* 76 kDa gene and that of the *C. pneumoniae* MOMP gene. It cannot be seen that this represents an undue burden on the Examiner for examination purposes. It is submitted that all species should be examined in this application.

However, having regard to the Examiner's requirement, applicants have made the election contained herein. This election is made without prejudice to applicant's right, should a generic claim be allowed, to have other species considered.

Respectfully submitted,

SIM & McBURNEY

BY: M.I. Stewart
M.I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada,
(416) 595-1155
FAX No. (416) 595-1163